contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


circio-holding-asa-first-half-2024-results

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Targovax

Oslo, Norway, 29 August 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA gene therapies, today announces its first half-year 2024 results.Circio's...

<div class="abstract">Oslo, Norway, 29 August 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA gene therapies, today announces its first half-year 2024 results.Circio's management will present the results in a live-streamed webcast at 10:00 am CEST to investors, analysts and the press. Click here for access to the live webcast&nbsp;(<a href="http://teams.microsoft.com/l/meetup-join/19%3ameeting_N2U2Njg5OTYtYjZjMC00MDBlLThlMjUtZjg4MTQwOTYzMDUy%40thread.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d">http://teams.microsoft.com/l/meetup-join/19%3ameeting_N2U2Njg5OTYtYjZjMC00MDBlLThlMjUtZjg4MTQwOTYzMDUy%40thread.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d</a>)Questions can be submitted by email in advance (to: lubor.gaal@circio.com)and during the presentation.Reporting material attached to this press release:<ul><li>Circio first-half year report 2024</li><li>Circio 1H24 webcast presentation</li></ul>The report and presentation are also available at&nbsp;www.circio.com***</div>First half-year 2024 highlightsCorporate<ul><li>In January, Business Finland approved Circio's application for a waiver of three R&amp;D loans totaling NOK 71.3 million</li><li>In May, launched a financing transaction securing cash runway for 12 months through a rights issue and parallel commitment from Atlas Capital Markets</li><li>Cash burn of NOK 19 million, representing a 68% reduction versus 1H23</li></ul>Circular RNA<ul><li>In April, announced technical in vivo proof-of-concept for its proprietary circVec circular RNA platform with &gt;4-month expression durability</li><li>In May, presented two circVec posters at the American Society of Gene &amp; Cell Therapy (ASGCT) 2024 annual meeting in Baltimore, USA</li><li>In June, announced a new generation circVec 2.2, achieving 2-4-fold higher expression than v2.1 and up to 15x improvement over mRNA expression</li></ul>Mutant KRAS<ul><li>In February, announced that the first patient was dosed in the Georgetown University Phase 2 study, testing TG01 in a triple combination in collaboration with Janssen and BMS</li><li>In March, the Chinese National Medical Products Administration (NMPA) approved the investigational new drug (IND) application of TG01</li></ul>***

Circio Holding ASA: First half 2024 results

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Stay up to date with our newsletter